Germ Cell Tumours: Difference between revisions
Urology4all (talk | contribs) |
Urology4all (talk | contribs) |
||
| Line 752: | Line 752: | ||
*** '''CSIIB with lymph node >3cm: chemotherapy''' | *** '''CSIIB with lymph node >3cm: chemotherapy''' | ||
* Routine surveillance CT imaging is unnecessary after complete resolution of disease. | * Routine surveillance CT imaging is unnecessary after complete resolution of disease. | ||
*Surgery in Early Metastatic Seminoma (SEMS) Trial | *'''Surgery in Early Metastatic Seminoma (SEMS) Trial''' | ||
**Study design: Phase II trial | **Study design: Phase II trial | ||
**55 patients with pure testicular seminoma after radical orchiectomy with isolated retroperitoneal lymphadenopathy 1-3 cm in greatest dimension. | **55 patients with pure testicular seminoma after radical orchiectomy with isolated retroperitoneal lymphadenopathy 1-3 cm in greatest dimension. | ||
| Line 762: | Line 762: | ||
***Median follow-up after RPLND: 33 months | ***Median follow-up after RPLND: 33 months | ||
***In post-RPLND follow-up, one patient received a single cycle of carboplatin for pN2, all other patients were managed with surveillance | ***In post-RPLND follow-up, one patient received a single cycle of carboplatin for pN2, all other patients were managed with surveillance | ||
***2-year relapse-free survival: 81% | ***Pathological nodal stage | ||
****pN0: 16% | |||
****pN1: 22% | |||
****pN2: 56% | |||
****pN3: 5% | |||
***2-year relapse-free survival: 81% (86% cN1 vs. 64% cN2, p=0.04) | |||
***2-year overall survival: 100% | ***2-year overall survival: 100% | ||
** | **[https://pubmed.ncbi.nlm.nih.gov/36913642/ Daneshmand, Siamak, et al.] "Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy." ''Journal of Clinical Oncology'' (2023): JCO-22. | ||
===== CSIIC and III seminoma ===== | ===== CSIIC and III seminoma ===== | ||